Team
People with deep sector expertise and a shared commitment to value creation.
Our team combines investment, operational and scientific experience to support companies and investors through critical moments of growth and transition.
Management team
Partners.

Dr. David Karabelnik
Founder & CEO · Zurich
Entrepreneur and corporate finance specialist in life sciences and pharma. Founder and CEO of Breslin AG; previously founder of Breslin Biotech AG, a life sciences venture firm launched with Dresdner-Allianz. He has held six board seats, including GPC Biotech and 4SC, advised and invested for Deutsche Bank and Commerzbank, and led two companies through IPOs. Co-founder of Anawa Laboratories, later acquired by MDS Pharma Services. PhD in biochemistry, ETH Zurich.

Dr. Detlef Wollweber
Life Sciences · Pharma · Agro
With Breslin since 2013. Former CEO of Bayer Innovation GmbH and Bayer Innovation Ventures, with advisory roles at Bayer Pharma, Bayer CropScience and Fraunhofer ISC. Earlier head of research at Bayer CropScience. PhD in organic chemistry, Ruhr University Bochum; named on more than 30 patents; lectured at the University of Düsseldorf for over a decade.

Klaus Berding
Corporate Finance · Life Sciences & Technology
More than 25 years in banking and consulting. Part of Breslin’s operating team since 2005; since 2003 he has led his own corporate finance firm, LSFA. Earlier SVP and Director at Dresdner Kleinwort in the Chemicals and Healthcare group, where he helped expand the bank’s international equity and IPO business across more than 40 transactions. Co-founder and board member of Amypopharma. MBA, Ruhr University Bochum; DVFA postgraduate degree.

Dr. Martin Schnee
Financial Analysis · Chemistry & Biotech
Associated partner since 2010 and founder of Schnee Research, working with AlphaValue, Europe’s largest independent research house. Earlier analyst roles at Commerzbank covering biotech, pharma, medtech and chemicals. PhD in chemistry, Goethe University Frankfurt; certified credit and biotech equity analyst; member of DVFA, GDCh and CLIB; non executive director at a German gene therapy company.

Dr. Francis Chen
Life Sciences & Venture Capital · San Francisco
Board member since 2006 of Mighty Therapeutics (formerly Stealth BioTherapeutics), developer of the first FDA-approved therapy for Barth syndrome. Former Vice Chairman of WI Harper Group, a venture firm active in Silicon Valley and Greater China. Over 20 years in healthcare management at Becton Dickinson and Baxter. PhD in immunology, Harvard University; MS and BS in chemistry, Tufts University.

Nathan Breslin
Strategic Development & Fundraising · Zurich
Finance and legal specialist in transactions, investment strategy and corporate growth. Supports buy side secondaries and manages the strategic and financial aspects of transactions, including contract negotiation and growth planning.
Advisory team
Sector advisors.
David Toledo
Private & Public Equity · Zurich
Finance and legal professional in private equity transactions, investment strategy and corporate advisory: due diligence, valuation, fundraising and secondaries, with end to end execution.
Dr. Herve de Kergrohen
Life Sciences & Investment Banking · Lausanne
More than 25 years in life sciences and asset management. Fund manager at CDC Innovation and BB Medtech among others, founder of several European biotech companies and of the Biodata conference in Geneva. Medical degree; MBA, INSEAD.
Dr. Manfred Kircher
Industrial Biotech & Speciality Chemicals · Düsseldorf
More than 25 years in senior roles at Evonik and Degussa. Former chairman of CLIB 2021, the international industrial biotech association, and portfolio manager for the Burrill Nutraceutical Fund. PhD in molecular genetics.
Christoph Kayenburg
Private & Public Equity · Munich
Specialist in commercial and investment banking, including five years at DG Bank in Tokyo and capital markets work in South Korea and London. Chairman of Krayenburg AG, Munich. Master in economics.
Dr. Jakob Karp
Medical Technology · Munich
Twenty years developing tools, systems and methods for orthodontic and medtech applications, alongside teaching and market communication for the dental and medtech markets. PhD in orthodontics.
Speak with the partner closest to your question.
Enquiries reach the team directly. There is no client services layer in between.
Contact us